Insider · CIK 0001410781
John Johnson
Files at AXGN (Axogen, Inc.), VSTM (Verastem, Inc.), APLT (Applied Therapeutics, Inc.), XERS (Xeris Biopharma Holdings, Inc.). First filing Jun 11, 2025, latest Jun 11, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AXGN: Axogen, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Axogen, Inc. | $43k 4,073 shares | -14% | 0% from low-48% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 19, 2025 | AXGN Axogen, Inc. | AGrant or award Restricted Stock Unitsderivative | +14,150 | $0.00 | $0 | 14,150 | Jun 20, 2025 |
| Jun 9, 2025 | AXGN Axogen, Inc. | SOpen-market sale Common Stock | -4,073 | $10.61 | $43k | 24,943 | Jun 11, 2025 |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 940,983 | Jun 4, 2025 |
| May 22, 2025 | VSTM Verastem, Inc. | AGrant or award Common Stock | +8,333 | $0.00 | $0 | 16,666 | May 27, 2025 |
| May 22, 2025 | VSTM Verastem, Inc. | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 27, 2025 |
| Dec 19, 2024 | APLT Applied Therapeutics, Inc. | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 500,000 | Dec 20, 2024 |
| Dec 19, 2024 | APLT Applied Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,000,000 | $0.00 | $0 | 1,000,000 | Dec 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.